CD70在初诊弥漫大B细胞淋巴瘤中的表达及临床意义  

CD70 expression in initially diagnosed diffuse large B cell lymphoma and its clinical significance

作　　者：王蒙 朱俊锋[1] 伍燕平 朱清[2] 张平平 朱太岗[3] 葛洪峰[4] 周黎黎[1] 李佳佳[1] 桑威 淮海淋巴瘤协作组 WAND Meng;ZHU Junfeng;WU Yanping;ZHU Qing;ZHANG Pingping;ZHU Taigang;GE Hongfeng;ZHOU Lili;LI Jiajia;SANG Wei;Huaihai Lymphoma Working Group(Department of Hematology,the First Affiliated Hospital of Bengbu Medical College,Bengbu,Anhui 233000,China;Department of Pathology,the First Affiliated Hospital of Bengbu Medical College;Department of Hematology,General Hospital of Wanbei Coal Electricity Group,Suzhou,Anhui 234000;Department of Hematology,Bozhou People′s Hospital,Bozhou,Anhui 236000;Department of Hematology,the Affiliated Hospital of Xuzhou Medical University,Xuzhou,Jiangsu 221002;不详)

机构地区：[1]蚌埠医学院第一附属医院血液科,安徽蚌埠233000 [2]蚌埠医学院第一附属医院病理科 [3]皖北煤电集团总医院血液科,安徽宿州234000 [4]亳州市人民医院血液科,安徽亳州236000 [5]徐州医科大学附属医院血液科,江苏徐州221002 [6]不详

出　　处：《徐州医科大学学报》2024年第1期66-71,共6页Journal of Xuzhou Medical University

基　　金：江苏省科技厅社会发展重点项目(BE2019638);蚌埠医学院自然科学重点项目(2022byzd053)。

摘　　要：目的 分析CD70在弥漫大B细胞淋巴瘤(DLBCL)中的表达情况,并探讨其与临床预后的相关性。方法 选取2017年1月—2021年12月蚌埠医学院第一附属医院收治的初诊DLBCL患者116例,收集临床资料进行回顾性分析。检测肿瘤组织中CD70的表达情况,分析CD70表达在DLBCL患者中的临床意义。结果 116例DLBCL患者中CD70阳性表达率为80.17%,其表达与中期评估疗效、有无B症状、骨髓是否受累、Ann Arbor分期相关(P<0.05),而与性别、年龄、乳酸脱氢酶(LDH)、β2-微球蛋白(β2-MG)、B细胞淋巴瘤因子-2(BCL-2)、BCL-6、Ki-67、Hans分型、原发部位、国际预后指数(IPI)评分无显著相关性(P>0.05)。生存分析显示,CD70阳性组与CD70阴性组无进展生存期(PFS)和总生存期(OS)比较,差异有统计学意义(P<0.05),CD70阳性组患者预后更差。单因素分析显示,中期评估疗效、LDH、β2-MG、Ki-67、Hans分型、Ann Arbor分期、IPI评分及CD70表达影响患者预后。多因素分析显示,中期评估疗效、Ki-67、Hans分型、CD70是患者PFS的独立预后因素,中期评估疗效、β2-MG、Ki-67、Hans分型和CD70是患者OS的独立预后因素。结论 CD70在DLBCL中呈高表达,且与不良预后密切相关。Objective To analyze the expression of CD70 in diffuse large B cell lymphoma(DLBCL)and its correlation with clinical prognosis.Methods A total of 116 patients newly diagnosed with DLBCL who were admitted to the First Affiliated Hospital of Bengbu Medical College from January 2017 to December 2021 were selected and their clinical data were retrospectively analyzed.The expression of CD70 in tumor tissues was detected,and the clinical significance of CD70 expression in DLBCL patients was analyzed.Results The positive expression rate of CD70 in 116 DLBCL patients was 80.17%,and its expression was related to mid-term efficacy,B symptoms,bone marrow involvement and Ann Arbor stage(P<0.05).However,CD70 expression was not associated with sex,age,lactate dehydrogenase(LDH),β2-microglobulin(β2-MG),B-cell lymphoma-2(BCL-2),BCL-6,Ki-67,Hans classification,primary site and international prognostic index(IPI)score(P>0.05).Survival analysis showed that the progression free survival(PFS)and overall survival(OS)of the CD70 positive group were significantly higher than those in the CD70 negative group(P<0.05),and the prognosis of CD70 positive patients was worse.According to univariate analysis,the prognosis of DLBCL patients was affected by efficacy,LDH,β2-MG,Ki-67,Hans classification,Ann Arbor stage,IPI score and CD70 expression.Multivariate analysis showed that mid-term efficacy,Ki-67,Hans classification and CD70 were the independent prognostic factors for PFS,and mid-term efficacy,β2-MG、Ki-67、Hans subtype and CD70 were the independent prognostic factors for OS.Conclusions CD70 is highly expressed in DLBCL and strongly associated with poor prognosis.

关 键 词：CD70 弥漫大B细胞淋巴瘤 预后 无进展生存期 总生存期 

分 类 号：R733.4[医药卫生—肿瘤]